

Ranbaxy fy 2010 pat at \$327 mn ₹14,968 mn, up on strong earnings

[Feb 22, 2011:](#)

Daiichi Sankyo Company Limited (hereafter, Daiichi Sankyo) and Ranbaxy Laboratories Limited (hereafter, Ranbaxy) today announced the start of synergistic initiative to leverage Ranbaxy's presence in Singapore to market innovative products originally discovered by Daiichi Sankyo.

Effective March 1, 2011, Ranbaxy will market four products of Daiichi Sankyo origin, including Cravit® (levofloxacin) tab and Cravit® IV in Singapore. The products were previously commercialized by Kyowa Hakko Bio Singapore Pte Ltd (hereafter, Kyowa Hakko Bio) in the country. Early this year, Daiichi Sankyo and Kyowa Hakko Bio had agreed to transfer the marketing rights of the products from Kyowa Hakko Bio to Ranbaxy.

"We are pleased to announce the first synergistic business development with Ranbaxy in ASEAN," said Joji Nakayama, President & CEO of Daiichi Sankyo. "We are determined to work with Ranbaxy to further serve diversifying medical needs in this strongly emerging region."

Commenting on the development, Arun Sawhney, Managing Director of Ranbaxy, said, "Ranbaxy has a strong foot hold in the ASEAN region. We will use our marketing strengths to offer innovative medicines from Daiichi Sankyo in this fast growing region, beginning with Singapore. This move will definitely widen our product offering while deepening our commitment to doctors and patients. I believe we will see many more synergies in time, emerging from our Hybrid Business Model with Daiichi Sankyo."

Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that is used to treat a broad range of infections. Originally discovered by Daiichi Sankyo, levofloxacin was first launched in Japan in 1993 under the brand name Cravit®. Levofloxacin is currently available in more than 120 countries worldwide.

About Daiichi Sankyo The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com

About Ranbaxy Laboratories Limited Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international

pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.

- Global sales in 2010 were \$1,868 Mn (₹85,507 Mn), reflecting a growth of 23% over the previous year. In Rupee terms, sales grew by 16%. Emerging markets accounted for 50% of sales during the year, while developed markets contributed 44%
- North America recorded sales of \$660Mn (₹30,226 Mn) for the year, a growth of 67%.
- In USA, sales for the year were \$600 Mn (₹27,448 Mn), a growth of 80% .
- Business in Europe continues to be competitive for generic companies. In Europe, the Company recorded sales of \$272 Mn (₹ 12,432 Mn) for the year, representing a growth of 1% in \$ terms.
- The India Pharma business recorded sales of ₹17,593 Mn (\$384 Mn), a growth of 8% over the previous year. Of this, the Global Consumer Healthcare business recorded sales of ₹2,485 Mn (\$54 Mn), a growth of 17% for the year. All key brands in this portfolio witnessed growth at market level. Revital, the company's flagship brand, is now the 6th largest product in the Indian Pharmaceutical market.
- The CIS region recorded sales of \$101 Mn (₹4,628 Mn), a growth of 18% for the year.
- Africa region recorded sales of \$154 Mn (₹7,040 Mn), a growth of 23% for the year.,
- Latin America recorded sales of \$83 Mn (₹3,793 Mn), a growth of 17% for the year.
- API business registered sales of \$114 Mn (₹5,238 Mn), a growth of 3% for the year.

Outlook: During 2011, the Company expects to achieve base case sales of approximately \$1.87 Bn (₹84 Bn).

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to

proprietary “platform technologies,” resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.

Sonke Pharmaceuticals

Sonke Pharmaceuticals (Pty) Ltd is a marketer and distributor of generic antiretroviral (ARV) medication in South Africa, Namibia and Botswana. The company is a proud Black Economic Empowerment, level 1 contributor with an AAA+ Empowerdex rating. It was established in January 2006 through a BEE joint venture between Ranbaxy (Pty) Ltd and Community Investment Holdings (CIH)

Community Investment Holdings

Community Investment Holdings (Pty) Ltd (CIH) was established in 1995 by Dr Anna Mokgokong and Joe Madungandaba. The company has moved from its humble origins to being a leading empowerment concern, with operations in South Africa, sub-Saharan Africa and globally.

Ranbaxy (S.A.) (Pty) Ltd., based in Centurion, South Africa, is a wholly owned subsidiary of Ranbaxy Laboratories Limited and is ranked No 5 amongst Generic companies. Ranbaxy South Africa is engaged in the sale and distribution of generic prescription products in the South African healthcare system. Additionally, the Company also offers high quality, affordable, generic Anti HIV medicines (ARVs) to the needy patients in Africa, supporting African Government’s in their efforts to control the AIDS epidemic. Ranbaxy has invested around USD 100 Mn in South Africa.

Ranbaxy Laboratories Limited, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary “platform technologies,” resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.